Online citations, reference lists, and bibliographies.
← Back to Search

The Relationship Between Treatment Cost And Prognosis Of Malignant Pleural Mesothelioma In Turkey

A. Guntulu, S. Metintaş, Tunc Kose, Filiz Bogar, Nuray Girginer, H. Batırel, Nurullah Uçkun, M. Metintas
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND: Malignant pleural mesothelioma (MPM) is endemic in the population exposed to asbestos and has high health-care cost with a limited life expectancy. The aim of this study is to evaluate the relationship between cost according to treatment type and prognosis in MPM. MATERIALS AND METHODS: A total of 309 patients with MPM were evaluated. Direct medical costs were estimated as the sum of hospital bills attributed to MPM for all patients followed up from hospital application to death. Three treatment strategies were compared to each other in terms of survival and median incremental costs per month gained cost. RESULTS: The mean age of the patients was 63.2 ± 11.2 years. The total median costs per patient and median survivals were $1838 and 5 months, $10,540 and 11 months, and $17,022 and 22 months for the best supportive care, the chemotherapy, and the multimodality groups, respectively. Factors affecting the cost of MPM were histology, treatment type, received second- and third-line chemotherapy, and number of hospitalization. CONCLUSION: MPM has a limited survival time despite treatment, and treatment cost is relatively high by prolongation of lifetime. Chemotherapy and multimodality approaches seem to be cost-effective until to be find more effective targeted therapies.
This paper references
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.5152/ttd.2015.10120136
Turkey Asbestos Control Strategic Plan Final Report.
(2015)
10.1093/ejcts/ezx122
Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma
Monica Casiraghi (2017)
10.1136/oemed-2016-104173
The economic burden of lung cancer and mesothelioma due to occupational and para-occupational asbestos exposure
E. Tompa (2017)
10.23749/mdl.v108i5.6505
Economic impact of malignant mesothelioma in Italy: an estimate of the public and social costs.
G. Buresti (2017)
10.1196/annals.1371.042
The Economic Costs of Health Service Treatments for Asbestos‐Related Mesothelioma Deaths
A. Watterson (2006)
10.1016/j.lungcan.2011.07.011
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Beth S Woods (2012)
10.1016/0169-5002(95)00508-0
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
10.1002/ajim.22106
Compensation of pleural mesothelioma in France: data from the French National Mesothelioma Surveillance Programme.
S. Chamming’s (2013)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.3390/ijerph13050494
Prevention of Asbestos-Related Disease in Countries Currently Using Asbestos
D. Marsili (2016)
10.1289/ehp.1002845
Global Magnitude of Reported and Unreported Mesothelioma
Eun-Kee Park (2011)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1016/j.jtcvs.2015.09.121
Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.
H. Batırel (2016)
10.1136/oemed-2017-104383
Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis
G. Marsh (2017)
10.1002/ajim.20705
Under-reporting of compensable mesothelioma in Alberta.
M. Cree (2009)
10.1186/s12885-015-1519-z
The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
G. Ak (2015)
10.1371/journal.pone.0190257
Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial
S. Stewart (2018)
10.1097/JTO.0b013e3181ba2033
Prognostic Factors According to the Treatment Schedule in Malignant Pleural Mesothelioma
Guntulu Ak (2009)
10.1183/16000617.0063-2016
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
A. Bibby (2016)
10.1016/j.jtho.2017.04.002
Epidemiology of Environmental Exposure and Malignant Mesothelioma.
Bian Liu (2017)
10.1080/15598608.2012.695571
Median-Based Incremental Cost-Effectiveness Ratio (ICER)
H. Bang (2012)
10.3390/ijerph14111293
Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program
S. Metintaş (2017)
10.1016/S1470-2045(16)30095-X
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
A. Clive (2016)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar